Black Diamond Therapeutics Management
Management criteria checks 2/4
Black Diamond Therapeutics' CEO is Mark Velleca, appointed in Sep 2023, has a tenure of less than a year. total yearly compensation is $3.39M, comprised of 5.3% salary and 94.7% bonuses, including company stock and options. directly owns 0.089% of the company’s shares, worth $306.57K. The average tenure of the management team and the board of directors is 2.4 years and 3.9 years respectively.
Key information
Mark Velleca
Chief executive officer
US$3.4m
Total compensation
| CEO salary percentage | 5.3% |
| CEO tenure | less than a year |
| CEO ownership | 0.09% |
| Management average tenure | 2.4yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 31
Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM
Jan 12Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation
Oct 26Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 05We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 16Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?
Oct 02Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
Jul 02We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully
Jan 16We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely
Jun 11Black Diamond Therapeutics EPS misses by $0.16
May 07We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Feb 26What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition
Jan 05Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?
Dec 01
Black Diamond nominates development candidate for glioblastoma program
Nov 20Black Diamond Therapeutics EPS beats by $0.02
Nov 10Black Diamond Therapeutics: One To Watch In Precision Oncology Space
Oct 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$180k | -US$82m |
| Sep 30 2023 | n/a | n/a | -US$84m |
| Jun 30 2023 | n/a | n/a | -US$83m |
| Mar 31 2023 | n/a | n/a | -US$87m |
| Dec 31 2022 | US$65k | n/a | -US$91m |
| Sep 30 2022 | n/a | n/a | -US$96m |
| Jun 30 2022 | n/a | n/a | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$121m |
| Dec 31 2021 | US$204k | n/a | -US$126m |
Compensation vs Market: Mark's total compensation ($USD3.39M) is above average for companies of similar size in the US market ($USD2.40M).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
CEO
Mark Velleca (59 yo)
less than a year
Tenure
US$3,387,383
Compensation
Dr. Mark A. Velleca, M. D., Ph. D., serves as President & Chief Executive Officer at Black Diamond Therapeutics, Inc. since September 16, 2023 and serves as its Chairman since December 2022. He has been an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | less than a year | US$3.39m | 0.089% $ 306.6k | |
| Co-Founder & Director | no data | US$2.02m | 1.74% $ 6.0m | |
| CFO, Principal Financial Officer and Chief Business Officer | 2.5yrs | US$1.49m | 0.24% $ 845.7k | |
| Chief Medical Officer | 1.9yrs | US$1.23m | 0% $ 0 | |
| Co-Founder & Chief Scientific Officer | 2.8yrs | US$347.30k | no data | |
| COO & General Counsel | 5yrs | US$911.23k | 0.016% $ 55.4k | |
| Chief People Officer | 2.3yrs | no data | no data | |
| Chief Development Officer | 1.5yrs | no data | no data | |
| Senior VP of Finance & Corporate Controller | 3.3yrs | no data | 0.0058% $ 20.1k |
2.4yrs
Average Tenure
51yo
Average Age
Experienced Management: BDTX's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 2.8yrs | US$3.39m | 0.089% $ 306.6k | |
| Co-Founder & Director | 7.7yrs | US$2.02m | 1.74% $ 6.0m | |
| Independent Director | 5.4yrs | US$68.14k | 0.098% $ 340.6k | |
| Independent Director | 7.2yrs | US$75.35k | 0.15% $ 505.2k | |
| Independent Director | 3.3yrs | US$109.35k | 0.019% $ 65.9k | |
| Lead Independent Director | 4.5yrs | US$59.35k | 0% $ 0 | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | less than a year | no data | 0% $ 0 |
3.9yrs
Average Tenure
58yo
Average Age
Experienced Board: BDTX's board of directors are considered experienced (3.9 years average tenure).